

RECEIVED
CENTRAL FAX CENTER
JUL 25 2006

Application No.	Filing Date	First Named Inventor	Attorney Docket No.	Responsive to Confirmation No.
10/688,585	10/18/2003	Deanna Jean Nelson	BLS21102	2265

1505 PRINCESS ANNE ROAD, RALEIGH, NC 27607 • 919-345-0339 • Fax 919-678-9474

25 July 2006

Mr. Everett White
Primary Examiner, Group Art Unit 1623
US Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

Transmitted by facsimile to 571-273-8300 on 25 July 2006

Dear Mr. White:

RE: Application No. 10/688,585
Filing Date: 10/18/2003
First Named Applicant: Deanna Jean Nelson
Title: Aminosalicylate Derivatives for Treatment of Inflammatory Bowel Disease


Responsive to the Office Action of 25 April 2006, which was made final. Claims 1-20 are pending in this application. Claims 8 and 10 are allowed. Claims 1-7, 9, and 11-20 stand rejected.

Applicant respectfully requests continued examination of the above-identified application under 37 CFR 1.114. A completed USPTO form "Request for Continued Examination" and fee are enclosed with this submission.

In a telephone communication with the Examiner on 27 June 2006, Applicant requested and was granted an interview with the Examiner in his office on 25 July 2006. In view of Applicant's Request for Continued Examination and her further amendments to the claims of the above-identified application, an interview may be premature. Therefore, Applicant respectfully withdraws her request for an interview at this time.

Affirmations

The Examiner has allowed Claims 8 and 10 and has affirmed that prior art of record does not teach or fairly suggest a therapeutic 5-aminosalicylic acid derivative composition having the general formula:



wherein R is a poly(ethylene glycol) chain-containing residue having the general formula $-\text{CH}_2\text{CH}_2\text{CH}_2-(\text{CH}_2\text{CH}_2\text{O})_n-\text{R}_1$, R_1 is H or a linear or branched lower alkyl group having from one to about 6 carbons, and n is a positive integer from about 3 to about 20 (Claim 8); and the method of preparing a therapeutic 5-aminosalicylic acid derivative composition of Claim 10.